Dr. Vishnu Garla, Associate Professor in the Division of Endocrinology, co-authored a paper out this month titled “Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial” in The Lancet Diabetes and Endocrinology. The article describes a randomized controlled trial to address whether Dapagliflozin, an SGLT2 inhibitor, might provide organ protection in patients with COVID-19 by affecting processes dysregulated during acute illness. In patients with cardiometabolic risk factors who were hospitalized with COVID-19, treatment with dapagliflozin did not result in a statistically significant risk reduction in organ dysfunction or death, or improvement in clinical recovery, but was well tolerated. Read the full article here.